Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors

Journal of Applied Toxicology

Volumn 27, Issue 2, 2007, Pages 133-142

  Jessen, Bart A ^a   Lee, Leo ^a   Koudriakova, Tatiana ^a   Haines, Morgan ^a   Lundgren, Karen ^a   Price, Sharon ^a   Nonomiya, Jim ^a   Lewis, Cristina ^a   Stevens, Gregory J ^a  

^a PFIZER INC   (United States)

Author keywords

CDK; Cyclin dependent kinase; Drug discovery; Leukocytes; Monkey; Mouse; Peripheral white blood cells; Rat

Indexed keywords

AG 012917; AG 012986; AG 024104; AG 024322; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; CELL ACTIVITY; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; MONKEY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; RODENT; SINGLE DRUG DOSE; TARGET CELL; TOXICOKINETICS;

ANIMALS; BENZAMIDES; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

RATTUS; RODENTIA;

EID: 33947577413     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1177     Document Type: Article

References (21)

1. Alegria LA, Chong WKM, Chu SS, Duvadie RK, Li L, Romines WH III, Yang Y. 2004. Preparation of N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors. WO 2004074283 A1.
2. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF, Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA. 1998. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482-2490.
3. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA. 2005. Cancer and Leukemia Group B. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res. 11: 4176-4181.
4. Cragg GM, Newman DJ. 2004. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 67: 232-244.
5. Dai Y, Grant S. 2004. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr. Oncol. Rep. 6: 123-130.
6. Huitema AD, Smits KD, Mathot RA, Schellens JH, Rodenhuis S, Beijnen JH. 2000. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs 11: 515-533.
7. Illanes O, Anderson S, Niesman M, Zwick L, Jessen BA. 2006. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicol. Pathol. 34: 243-248.
8. Jimenez JJ, Huang HS, Hindahl M, Pearson FC, Yunis AA. 1992. Protection from chemotherapy-induced neutropenia by Imu Vert. Am. J. Med. Sci. 303: 83-85.
9. Kephart SE, McAlpine IJ, Reich SH. 2006. 3,5-Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. U.S. Patent 7008953.
10. Li B, Liu Y, Uno T, Gray N. 2004. Creating chemical diversity to target protein kinases. Comb. Chem. High Throughput Screen. 7: 453-472.
11. Li L, Reich SH, Wallace MB, Alegria LA, Yang Y, Chu SS, Bleckman TM, Chong WKM, Duvadie RK, Romines WH III. 2004. Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation. U.S. Patent 6720346.
12. Molineux G. 2003. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14: 259-264.
13. Pommier Y. 1993. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 32: 103-108.
14. Ramiro-Ibanez F, Trajkovic D, Jessen B. 2005. Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol. Pathol. 33: 784-791.
15. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D. 2001. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. 19: 1985-1992.
16. Senderowicz AM. 2004. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 16: 670-678.
17. Sharp PE, LaRegina. 1998. The Laboratory Rat: The Laboratory Animal Pocket Reference Series. CRC Press: Boca Raton.
18. Suckow MA, Danneman P, Brayton C. 2001. The Laboratory Mouse: The Laboratory Animal Pocket Reference Series. CRC Press: Boca Raton.
19. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM. 2002. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol. 20: 4074-4082.
20. Walker JV, Nitiss JL. 2002. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 20: 570-589.
21. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ. 2001. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin. Cancer Res. 7: 2301-2308.